TRIGR Therapeutics, Inc
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From TRIGR Therapeutics, Inc
Private Company Edition: Perceptive/Xontogeny, Abingworth, Kizoo and Droia closed venture capital funds. New biopharma VC financings also include a $105m series C round for Elpiscience and $92m for newly launched Interline.
Plus deals involving Helixmith/Wacker, Sosei Heptares/Metrion, Ono/Ribon, Asahi Kasei/Lilly, Citrine/Diurnal, Mitsubishi Tanabe/Aquestive, Immunotech/T-Cure, TRIGR/Elpiscience, Daiichi Sankyo/ViGeneron
Scrip takes a look at Korean out-licensing deal trends and rankings in 2018, finding biotech-related transactions were dominant.
As the year end approaches, Scrip wraps up what major events made headlines in the South Korean pharma/biotech sector in 2018.
- Large Molecule
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.